| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 208 | 2024 | 1624 | 34.100 |
Why?
|
| Pyrazoles | 48 | 2024 | 1985 | 7.680 |
Why?
|
| Pyrimidines | 55 | 2024 | 2954 | 7.490 |
Why?
|
| Piperidines | 57 | 2024 | 1634 | 5.390 |
Why?
|
| Adenine | 51 | 2024 | 976 | 4.950 |
Why?
|
| Purines | 24 | 2022 | 590 | 4.350 |
Why?
|
| Quinazolinones | 23 | 2022 | 222 | 4.080 |
Why?
|
| Antineoplastic Agents | 67 | 2024 | 13531 | 3.980 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 60 | 2024 | 11539 | 3.610 |
Why?
|
| Protein Kinase Inhibitors | 45 | 2024 | 5609 | 3.420 |
Why?
|
| Vidarabine | 20 | 2024 | 333 | 2.690 |
Why?
|
| Lymphoma, B-Cell | 13 | 2024 | 925 | 2.320 |
Why?
|
| Sulfonamides | 19 | 2024 | 1949 | 2.240 |
Why?
|
| Protein-Tyrosine Kinases | 17 | 2023 | 2417 | 2.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 17 | 2023 | 1405 | 2.160 |
Why?
|
| Cyclophosphamide | 16 | 2024 | 2198 | 1.720 |
Why?
|
| Lymphoma, Non-Hodgkin | 14 | 2022 | 1377 | 1.680 |
Why?
|
| Chromosome Deletion | 13 | 2019 | 1389 | 1.630 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 13 | 2023 | 1392 | 1.610 |
Why?
|
| Pyrazines | 11 | 2022 | 1192 | 1.590 |
Why?
|
| Drug Resistance, Neoplasm | 21 | 2024 | 5164 | 1.570 |
Why?
|
| Benzamides | 10 | 2022 | 1341 | 1.540 |
Why?
|
| Phosphatidylinositol 3-Kinases | 15 | 2024 | 2867 | 1.480 |
Why?
|
| Receptors, Antigen, B-Cell | 6 | 2017 | 547 | 1.380 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 2018 | 422 | 1.300 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 6 | 2022 | 884 | 1.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2023 | 5465 | 1.190 |
Why?
|
| Lymphoma, Mantle-Cell | 8 | 2021 | 238 | 1.150 |
Why?
|
| Lymphoma, Follicular | 7 | 2023 | 446 | 1.140 |
Why?
|
| Chromosome Aberrations | 6 | 2019 | 1771 | 1.140 |
Why?
|
| Immunotherapy | 12 | 2023 | 4594 | 1.090 |
Why?
|
| Humans | 272 | 2024 | 746070 | 1.050 |
Why?
|
| Molecular Targeted Therapy | 11 | 2021 | 2777 | 1.040 |
Why?
|
| Isoquinolines | 4 | 2021 | 350 | 1.000 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 10 | 2017 | 692 | 0.990 |
Why?
|
| Quinoxalines | 2 | 2018 | 286 | 0.960 |
Why?
|
| Lymphoma | 7 | 2021 | 1872 | 0.920 |
Why?
|
| Lymphocytosis | 1 | 2024 | 121 | 0.880 |
Why?
|
| Neoplasm, Residual | 8 | 2023 | 983 | 0.870 |
Why?
|
| Remission Induction | 12 | 2021 | 2361 | 0.860 |
Why?
|
| B-Lymphocytes | 16 | 2024 | 4671 | 0.860 |
Why?
|
| Immunoglobulin Heavy Chains | 9 | 2019 | 649 | 0.820 |
Why?
|
| Aged | 94 | 2024 | 164222 | 0.770 |
Why?
|
| Atrial Fibrillation | 9 | 2024 | 5050 | 0.760 |
Why?
|
| Immunoglobulin Variable Region | 6 | 2022 | 417 | 0.740 |
Why?
|
| Pyrimethamine | 1 | 2021 | 93 | 0.740 |
Why?
|
| Thalidomide | 4 | 2017 | 881 | 0.720 |
Why?
|
| Middle Aged | 101 | 2024 | 214419 | 0.720 |
Why?
|
| Mutation | 28 | 2023 | 29620 | 0.710 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2023 | 3011 | 0.700 |
Why?
|
| In Situ Hybridization, Fluorescence | 9 | 2016 | 2518 | 0.690 |
Why?
|
| Aged, 80 and over | 53 | 2024 | 57552 | 0.680 |
Why?
|
| Transaminases | 1 | 2020 | 191 | 0.680 |
Why?
|
| Treatment Outcome | 58 | 2024 | 63664 | 0.680 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2018 | 578 | 0.680 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 4 | 2022 | 179 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2023 | 2429 | 0.670 |
Why?
|
| Recurrence | 22 | 2023 | 8373 | 0.650 |
Why?
|
| Gene Expression Regulation, Leukemic | 10 | 2021 | 646 | 0.640 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3609 | 0.630 |
Why?
|
| Heterocyclic Compounds | 1 | 2019 | 245 | 0.620 |
Why?
|
| Male | 120 | 2024 | 351098 | 0.610 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2019 | 408 | 0.610 |
Why?
|
| Phospholipase C gamma | 1 | 2018 | 124 | 0.600 |
Why?
|
| Signal Transduction | 21 | 2024 | 23115 | 0.600 |
Why?
|
| Enzyme Inhibitors | 8 | 2021 | 3695 | 0.580 |
Why?
|
| Female | 117 | 2024 | 382129 | 0.570 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 867 | 0.550 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2021 | 2887 | 0.550 |
Why?
|
| Transplantation Conditioning | 11 | 2019 | 1568 | 0.550 |
Why?
|
| Antigens, CD20 | 4 | 2022 | 202 | 0.540 |
Why?
|
| Th17 Cells | 1 | 2023 | 768 | 0.540 |
Why?
|
| Prognosis | 34 | 2022 | 29072 | 0.530 |
Why?
|
| Autoimmunity | 2 | 2021 | 1332 | 0.530 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1837 | 0.530 |
Why?
|
| Disease-Free Survival | 22 | 2019 | 6781 | 0.520 |
Why?
|
| Adult | 78 | 2024 | 214969 | 0.520 |
Why?
|
| Hemorrhage | 6 | 2023 | 3522 | 0.510 |
Why?
|
| Clinical Trials as Topic | 12 | 2024 | 7935 | 0.510 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2015 | 44 | 0.510 |
Why?
|
| Transplantation, Autologous | 11 | 2023 | 2109 | 0.500 |
Why?
|
| Transplantation, Homologous | 10 | 2020 | 4617 | 0.490 |
Why?
|
| Waldenstrom Macroglobulinemia | 6 | 2016 | 1066 | 0.490 |
Why?
|
| Acrylamides | 1 | 2016 | 258 | 0.470 |
Why?
|
| Immunoglobulins | 1 | 2017 | 862 | 0.470 |
Why?
|
| Flow Cytometry | 6 | 2023 | 5837 | 0.470 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 1478 | 0.470 |
Why?
|
| Sequence Deletion | 1 | 2018 | 1491 | 0.470 |
Why?
|
| Graft vs Host Disease | 7 | 2020 | 2931 | 0.460 |
Why?
|
| Antigens, Neoplasm | 2 | 2021 | 1974 | 0.460 |
Why?
|
| Stem Cell Transplantation | 7 | 2023 | 1597 | 0.460 |
Why?
|
| Bone Marrow Transplantation | 3 | 2007 | 2676 | 0.440 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 442 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 11 | 2023 | 9103 | 0.430 |
Why?
|
| Home Care Services | 1 | 2019 | 622 | 0.430 |
Why?
|
| Drug Discovery | 3 | 2017 | 1055 | 0.420 |
Why?
|
| Antibodies, Neoplasm | 2 | 2011 | 279 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2019 | 3610 | 0.420 |
Why?
|
| Hypertension | 5 | 2024 | 8359 | 0.400 |
Why?
|
| Salvage Therapy | 6 | 2019 | 1265 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 9172 | 0.400 |
Why?
|
| Stromal Cells | 3 | 2015 | 1304 | 0.390 |
Why?
|
| Survival Rate | 18 | 2021 | 12632 | 0.380 |
Why?
|
| Survival Analysis | 15 | 2020 | 10127 | 0.380 |
Why?
|
| Genes, myc | 2 | 2012 | 392 | 0.380 |
Why?
|
| Disease Progression | 15 | 2023 | 13302 | 0.370 |
Why?
|
| Hodgkin Disease | 5 | 2021 | 1378 | 0.370 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 4704 | 0.370 |
Why?
|
| Follow-Up Studies | 26 | 2024 | 38752 | 0.370 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 2224 | 0.360 |
Why?
|
| Heart Diseases | 1 | 2022 | 2764 | 0.340 |
Why?
|
| Neutropenia | 5 | 2023 | 880 | 0.340 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2018 | 615 | 0.330 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 1529 | 0.320 |
Why?
|
| Neoplasm Staging | 12 | 2021 | 11064 | 0.320 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2014 | 124 | 0.310 |
Why?
|
| Cell Line, Tumor | 20 | 2024 | 16652 | 0.310 |
Why?
|
| Neoplasms | 8 | 2023 | 21681 | 0.310 |
Why?
|
| Translocation, Genetic | 2 | 2017 | 1379 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-fos | 4 | 1998 | 570 | 0.310 |
Why?
|
| Drug Administration Schedule | 9 | 2021 | 4858 | 0.300 |
Why?
|
| Flavonoids | 2 | 2015 | 441 | 0.300 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2007 | 25 | 0.300 |
Why?
|
| Apoptosis | 13 | 2021 | 9425 | 0.290 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2020 | 119 | 0.290 |
Why?
|
| Receptor, Insulin | 1 | 2011 | 834 | 0.290 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2007 | 80 | 0.280 |
Why?
|
| Bone Marrow | 4 | 2023 | 2901 | 0.280 |
Why?
|
| Leukemia, B-Cell | 2 | 2017 | 83 | 0.280 |
Why?
|
| Peritoneal Dialysis | 1 | 2007 | 145 | 0.270 |
Why?
|
| Combined Modality Therapy | 8 | 2018 | 8509 | 0.270 |
Why?
|
| Quality of Life | 4 | 2023 | 12985 | 0.270 |
Why?
|
| Etoposide | 2 | 2022 | 630 | 0.270 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 10018 | 0.270 |
Why?
|
| Hyperkalemia | 1 | 2008 | 224 | 0.260 |
Why?
|
| Immunologic Factors | 2 | 2017 | 1568 | 0.260 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 238 | 0.260 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 2001 | 0.260 |
Why?
|
| Whole-Body Irradiation | 2 | 2013 | 423 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 983 | 0.260 |
Why?
|
| Karyotyping | 5 | 2016 | 1184 | 0.250 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2018 | 324 | 0.250 |
Why?
|
| Alternative Splicing | 2 | 2023 | 1089 | 0.250 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 2 | 2018 | 57 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6453 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2021 | 10719 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2023 | 2055 | 0.230 |
Why?
|
| Vincristine | 2 | 2022 | 1029 | 0.230 |
Why?
|
| Time Factors | 13 | 2021 | 39589 | 0.230 |
Why?
|
| Thiazoles | 1 | 2011 | 1487 | 0.230 |
Why?
|
| Pubic Bone | 1 | 2003 | 31 | 0.220 |
Why?
|
| Chemokine CCL4 | 1 | 2023 | 128 | 0.220 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 3 | 2014 | 69 | 0.220 |
Why?
|
| Gene Expression Profiling | 7 | 2021 | 9313 | 0.220 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 1362 | 0.210 |
Why?
|
| Sequoia | 1 | 2022 | 6 | 0.210 |
Why?
|
| Animals | 32 | 2021 | 166308 | 0.210 |
Why?
|
| Genomics | 4 | 2022 | 5697 | 0.210 |
Why?
|
| Carcinoma, Small Cell | 2 | 2012 | 413 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 8359 | 0.210 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2013 | 475 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 4518 | 0.210 |
Why?
|
| Clone Cells | 4 | 2021 | 1652 | 0.200 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 316 | 0.200 |
Why?
|
| Ataxia Telangiectasia | 1 | 2022 | 106 | 0.200 |
Why?
|
| TNF Receptor-Associated Factor 4 | 1 | 2021 | 5 | 0.200 |
Why?
|
| MicroRNAs | 4 | 2022 | 3744 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2021 | 19 | 0.190 |
Why?
|
| Prednisone | 2 | 2022 | 1557 | 0.190 |
Why?
|
| Germ Cells | 2 | 2017 | 628 | 0.190 |
Why?
|
| Receptors, CXCR4 | 2 | 2016 | 729 | 0.190 |
Why?
|
| Bacteriocins | 2 | 2011 | 88 | 0.190 |
Why?
|
| Risk Factors | 14 | 2024 | 72413 | 0.190 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 719 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2022 | 848 | 0.180 |
Why?
|
| Growth Substances | 1 | 2002 | 769 | 0.180 |
Why?
|
| Lymphocyte Activation | 3 | 2021 | 5414 | 0.180 |
Why?
|
| Incidence | 5 | 2024 | 20812 | 0.180 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 589 | 0.180 |
Why?
|
| Enzyme Activation | 3 | 2021 | 3601 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 197 | 0.170 |
Why?
|
| DNA Methylation | 4 | 2020 | 4259 | 0.170 |
Why?
|
| Doxorubicin | 2 | 2022 | 2194 | 0.170 |
Why?
|
| Pneumocystis carinii | 1 | 2020 | 71 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 180 | 0.170 |
Why?
|
| Edema | 1 | 2023 | 755 | 0.170 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2019 | 35 | 0.170 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2001 | 339 | 0.170 |
Why?
|
| Receptors, Notch | 2 | 2021 | 734 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2016 | 17435 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 1053 | 0.160 |
Why?
|
| Drug Repositioning | 1 | 2021 | 229 | 0.160 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 76 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 612 | 0.160 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2020 | 243 | 0.160 |
Why?
|
| Leukemia, Lymphoid | 1 | 2018 | 309 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 870 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 2204 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 10095 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2019 | 216 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2016 | 15367 | 0.160 |
Why?
|
| Leukocyte Count | 2 | 2019 | 1580 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2014 | 1349 | 0.150 |
Why?
|
| Disease Management | 3 | 2017 | 2451 | 0.150 |
Why?
|
| Cytarabine | 4 | 2020 | 699 | 0.150 |
Why?
|
| Cohort Studies | 9 | 2019 | 40505 | 0.150 |
Why?
|
| Germ-Line Mutation | 2 | 2016 | 1814 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2021 | 500 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2012 | 5027 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 8 | 2021 | 6138 | 0.150 |
Why?
|
| Cyclopentanes | 2 | 2015 | 87 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2013 | 532 | 0.140 |
Why?
|
| Time | 1 | 2019 | 540 | 0.140 |
Why?
|
| Comorbidity | 5 | 2019 | 10348 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2016 | 352 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2020 | 376 | 0.140 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2012 | 865 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2018 | 387 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 2793 | 0.140 |
Why?
|
| Chemokine CXCL12 | 2 | 2016 | 450 | 0.140 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2016 | 17 | 0.140 |
Why?
|
| Retreatment | 2 | 2015 | 600 | 0.140 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2016 | 42 | 0.140 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 242 | 0.140 |
Why?
|
| Cyclin D1 | 1 | 1998 | 451 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-hck | 1 | 2016 | 46 | 0.140 |
Why?
|
| Thrombocytopenia | 2 | 2011 | 1158 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 188 | 0.130 |
Why?
|
| Lipoproteins | 1 | 2001 | 881 | 0.130 |
Why?
|
| Cytokines | 3 | 2021 | 7219 | 0.130 |
Why?
|
| Genes, Immediate-Early | 1 | 1996 | 101 | 0.130 |
Why?
|
| Chromosome Breakage | 1 | 2016 | 159 | 0.130 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2016 | 111 | 0.130 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 482 | 0.130 |
Why?
|
| NF-kappa B | 2 | 2015 | 2462 | 0.130 |
Why?
|
| HLA Antigens | 3 | 2020 | 1340 | 0.130 |
Why?
|
| Genome, Human | 3 | 2021 | 4359 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2022 | 3411 | 0.130 |
Why?
|
| Genomic Instability | 2 | 2017 | 688 | 0.130 |
Why?
|
| Chlorambucil | 1 | 2015 | 42 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 1065 | 0.130 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2015 | 659 | 0.120 |
Why?
|
| Age Factors | 4 | 2020 | 18145 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2023 | 11385 | 0.120 |
Why?
|
| CpG Islands | 3 | 2020 | 1200 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 2448 | 0.120 |
Why?
|
| Cytogenetics | 2 | 2016 | 198 | 0.120 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2015 | 178 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2021 | 4115 | 0.120 |
Why?
|
| Triazoles | 2 | 2018 | 903 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2015 | 6058 | 0.120 |
Why?
|
| Immunoglobulin M | 3 | 2015 | 1507 | 0.120 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 325 | 0.120 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2016 | 166 | 0.120 |
Why?
|
| Maternal Behavior | 1 | 1996 | 302 | 0.120 |
Why?
|
| Cell Cycle | 3 | 2010 | 2921 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2013 | 195 | 0.110 |
Why?
|